Differential activities of CC-122 in GCB-DLBCL compared with lenalidomide. (A) Effect of 10 μM lenalidomide exposure (log2 fold-change vs DMSO) plotted against 10 μM CC-122 exposure at 24 and 72 hours in TMD8 and WSU-DLCL2 cells. Key proteins (IKZF1, IKZF3) and proteins manifestly affected more by one compound than the other are displayed, along with r2 for linear regression. (B) DLBCL cells were treated with DMSO, lenalidomide (Len), or CC-122 for 72 hours. Cell lysates were separated by SDS-PAGE, and levels of Aiolos, Ikaros, IRF7, DDX58, and β-actin were assessed. (C) DLBCL cells were treated with DMSO, lenalidomide (10 μM), or CC-122 (10 μM) for 1, 6, or 12 hours. Cell lysates were separated by SDS-PAGE, and levels of Aiolos, Ikaros, and β-actin were assessed. (D) DLBCL cell lines were treated with DMSO, lenalidomide (1-10 μM), or CC-122 (0.1-10 μM) for 7 days, after which apoptosis was measured by Annexin V and To-Pro 3 flow cytometric analysis.
